<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selegiline: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selegiline: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Selegiline: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11043" href="/d/html/11043.html" rel="external">see "Selegiline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709409"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidal thoughts and behaviors (transdermal patch):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.</p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline transdermal patch is contraindicated in patients less than 12 years of age because of an increased risk of hypertensive crisis.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F220310"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Emsam;</li>
<li>Zelapar</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868214"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>TEVA-Selegiline [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F220352"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Parkinson Agent, MAO Type B Inhibitor;</li>
<li>
                        Antidepressant, Monoamine Oxidase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F220315"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b>
<b>Transdermal:</b> Initial: Apply 6 mg/24 hours patch once daily. Although the initial dose is the target dose, may increase daily dose based on clinical response in increments of 3 mg/day every 2 weeks up to a maximum of 12 mg/24 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b5b938e-b460-4c84-a5e0-87578ffd7345">Parkinson disease, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease, adjunctive therapy: Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsule, tablet: 5 mg twice daily with breakfast and lunch with concomitant carbidopa/levodopa therapy; maximum: 10 mg/day.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Initial: 1.25 mg once daily with concomitant carbidopa/levodopa therapy for at least 6 weeks; may increase to 2.5 mg once daily based on clinical response and tolerability (maximum: 2.5 mg/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ba6f3dba-5de6-42ac-9cfb-88c89d2a4984">Parkinson disease, monotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease, monotherapy (off-label use): Oral:</b> Capsule, tablet: 5 mg twice daily with breakfast and lunch; maximum: 10 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8417384','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8417384','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Due to its short half-life, withdrawal symptoms are possible after abrupt discontinuation; consider tapering to avoid withdrawal and assess for symptom recurrence. When discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over 4 weeks) include history of antidepressant withdrawal symptoms or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1','lexi-content-ref-Hirsch.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1','lexi-content-ref-Hirsch.1'])">Ref</a></span>). More severe symptoms have been associated with monoamine oxidase inhibitor (MAOIs); more conservative tapers may be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11347722','lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11347722','lexi-content-ref-15014601'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching antidepressants: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from selegiline, another MAOI</i>
<i>, or an alternative antidepressant:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days (or a time equal to 4 to 5 half-lives of the drug) to elapse between discontinuing another MAOI or an alternative antidepressant without long half-life metabolites (eg, tricyclic antidepressants, paroxetine, fluvoxamine, venlafaxine) and initiation of selegiline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 5 weeks to elapse between discontinuing fluoxetine (with long half-life metabolites) and initiation of selegiline.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing selegiline and initiation of another MAOI or an alternative antidepressant.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990950"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules, tablets: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 89 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">End-stage renal disease: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥15 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD requiring dialysis: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988290"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules/tablets: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate impairment (Child-Pugh class A and B): 1.25 mg once daily based on clinical response and tolerability.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment (Child-Pugh class C): Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment (Child-Pugh class A and B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F220316"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar): Transdermal:</b> 6 mg/24 hours once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsule, tablet: ≤5 mg/day (when combined with levodopa) is recommended by some clinicians to decrease the enhanced dopaminergic side effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11402154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11402154'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching antidepressants:</b> Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F220329"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae35da88-7e3c-40ea-9daa-1be1ccfd22b6">Depression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Depression: </b>Adolescents &gt;17 years: Transdermal: Refer to adult dosing.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching antidepressants:</b> Refer to adult dosing.</p></div>
<div class="block dorp drugH1Div" id="F51159983"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents ≥18 years: Transdermal:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥15 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">ESRD requiring dialysis: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51159984"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Adolescents ≥18 years: Transdermal:</p>
<p style="text-indent:0em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A and B): No dosage adjustment necessary.</p>
<p style="text-indent:0em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F220285"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults administered transdermal patch (TDP), orally disintegrating tablet (ODT), and oral (capsule/tablet: oral) formulations unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (ODT: 12% to 21%; TDP: 3% to 10%; including orthostatic hypotension)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (ODT: 11%; oral: 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site reaction (TDP: 24%; including application-site erythema)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (ODT: 11%; oral: ≤7%), headache (TDP: 18%; ODT/oral: 2% to 7%), insomnia (ODT/TDP: 7% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (ODT: 2%), hypertension (ODT: 3%), palpitations (oral: 2%), syncope (oral: ≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermal ulcer, dermatological disorder (ODT: 6%; including contact dermatitis, diaphoresis, fungal dermatitis, herpes simplex dermatitis, pruritus, skin hypertrophy, urticaria, xeroderma), ecchymosis (ODT: 2%), skin rash (ODT/TDP: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (ODT: 2%), weight loss (TDP: 5%; oral: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (oral: 4%), constipation (ODT: 4%), diarrhea (TDP: 9%; ODT/oral: 2%), dyspepsia (TDP: 4%; ODT: 5%), dysphagia (ODT: 2%), flatulence (ODT: 2%), oral mucosa changes (ODT: 10%; including mouth pain, odynophagia, oral mucosa ulcer, oral mucosal erythema), stomatitis (ODT: 5%), vomiting (ODT: 3%), xerostomia (TDP: 8%; ODT/oral: 3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Sexual disorder (TDP: males: anorgasmia [&lt;1%], decreased libido [&lt;1%], ejaculatory disorder [1%]), urinary retention (oral: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Ataxia (ODT: 3%), confusion (oral: 3%), depression (ODT: 2%), drowsiness (ODT: 3%), generalized ache or pain (oral: 2%), hallucination (ODT/oral: 3% to 4%; including visual hallucination), lethargy (oral: 2%), pain (ODT: 8%), tremor (ODT: 3%), vivid dream (oral: 2%; including abnormal dreams and nightmares)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (ODT: 5%), dyskinesia (ODT: 6%; including exacerbation of dyskinesia), lower back pain (oral: 2%), lower leg pain (oral: 2%), lower limb cramp (ODT: 3%), myalgia (ODT: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (ODT: 3%), pharyngitis (OTD/TDP: 3% to 4%), rhinitis (ODT: 7%), sinusitis (TDP: 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Manic reaction (TDP)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (including exacerbation of angina pectoris), cardiac arrhythmia, peripheral edema, sinus bradycardia, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, skin photosensitivity, unusual facial hair growth</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, decreased appetite, dysgeusia, gastrointestinal hemorrhage, heartburn, rectal hemorrhage, sore throat</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Benign prostatic hypertrophy, nocturia, urinary frequency, urinary hesitancy</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hematoma</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (including festinating gait and freezing of gait), amnesia, apathy, apraxia (increased), asthenia, behavioral changes, chills, chorea, delusions, facial grimace, fatigue, heaviness of the legs, irritability, loss of balance, malaise, migraine, mood changes, myasthenia, numbness of fingers, numbness of toes, overstimulation, personality changes, restlessness, sleep disturbance, sleep driving, speech disturbance, sudden onset of sleep, suicidal ideation, suicidal tendencies, tension, twitching, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bradykinesia, dystonia, muscle cramps, neck stiffness, tardive dyskinesia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharospasm, blurred vision, diplopia, supraorbital pain</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any formulation):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertensive crisis (Ito 2001)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased libido (Shapiro 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased white blood cell count (Mizuno 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (Montastruc 2000), anxiety (Mizuno 2019), atypical sexual behavior (paraphilia) (Shapiro 2006), delirium (Montastruc 2000), disorientation, disturbance in attention (Mizumo 2019), falling (Mizuno 2019), hypoesthesia, involuntary body movements (Montastruc 2000), sedated state (Montastruc 2000), seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen (Mizuno 2019)</p></div>
<div class="block coi drugH1Div" id="F220298"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to selegiline or any component of the formulation; concomitant use of meperidine.</p>
<p style="text-indent:-2em;margin-left:2em;">Orally disintegrating tablet: Concomitant use or within 14 days of other monoamine oxidase inhibitors or other drugs that are potent inhibitors of monoamine oxidase (including linezolid), or opioids (eg, meperidine, methadone, tramadol); concomitant use with cyclobenzaprine, dextromethorphan, or St John's wort.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: Pheochromocytoma; patients &lt;12 years of age; use of carbamazepine, serotonin reuptake inhibitors (including selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors), clomipramine, imipramine, tramadol, propoxyphene, meperidine, methadone, pentazocine, and dextromethorphan (concurrently, within 2 weeks of selegiline discontinuation, or selegiline use within 4 to 5 half-lives [approximately 1 week for most medications; 5 weeks for fluoxetine] of discontinuation of the contraindicated drug).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe psychosis; severe dementia; active peptic ulcer; extrapyramidal disorders, including excessive tremor or tardive dyskinesia.</p></div>
<div class="block war drugH1Div" id="F220282"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Major psychiatric warnings (transdermal patch):</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal thinking/behavior:</p>
<p style="text-indent:-2em;margin-left:6em;">- The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">- Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their health care provider if any of these symptoms or worsening depression or psychosis occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• BP effects: Oral formulations: May cause exacerbation of hypertension. May also cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Incidence of orthostatic hypotension may also be increased in older adults and when titrating the dose. Monitor patients for new onset or exacerbation of hypotension, new onset hypertension or hypertension not adequately controlled after starting selegiline.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving). Somnolence and falling asleep while engaged in activities of daily living (including operation of motor vehicles) have been reported with the orally disintegrating tablet; some cases reported that there were no warning signs for the onset of symptoms. Symptom onset may occur well after initiation of treatment; some events have occurred &gt;1 year after initiation of treatment. Prior to treatment initiation, evaluate for factors that may increase these risks such as concomitant sedating medications and the presence of sleep disorders. Monitor for drowsiness or sleepiness. If significant daytime sleepiness or episodes of falling asleep during activities that require active participation occur (eg, driving, conversations, eating), discontinue selegiline. There is insufficient information to suggest that dose reductions will eliminate these symptoms. If therapy is continued, advise patient to avoid driving and other potentially dangerous activities.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dyskinesia: Oral formulations: May potentiate the dopaminergic side effects of levodopa and cause dyskinesia or exacerbate preexisting dyskinesia requiring a reduction of the dose of levodopa.</p>
<p style="text-indent:-2em;margin-left:4em;">• Impulse control disorders: Dopaminergic agents used for Parkinson disease have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), uncontrolled spending of money, binge eating, and/or other intense urges. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/substance use disorders and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychosis: Orally disintegrating tablets: May cause new or worsening mental status and behavioral changes (may be severe) including hallucinations and psychotic-like behavior with initiation of therapy, after dose increases, or during the course of therapy. Symptoms may consist of paranoid ideation, delusions, hallucinations, confusion, psychotic-like behavior, disorientation, aggressive behavior, agitation, and delirium. Avoid use in patients with a major psychotic disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with concomitant use of serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, St. John's wort, tryptophan) or agents that impair metabolism of serotonin (eg, monoamine oxidase inhibitors [MAOIs] intended to treat psychiatric disorders, other MAOIs [ie, linezolid and IV methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile BP, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use oral products with caution in patients with hepatic impairment; dosage adjustments may be necessary with orally disintegrating tablets in patients with mild to moderate hepatic impairment (Child-Pugh class A and B); orally disintegrating tablets are not recommended in patients with severe hepatic impairment (Child-Pugh class C).</p>
<p style="text-indent:-2em;margin-left:4em;">• Mania/hypomania: Transdermal patch: May precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Combination therapy with an antidepressant and a mood stabilizer should also be avoided in acute mania or mixed episodes, as well as maintenance treatment in bipolar disorder due to the mood-destabilizing effects of antidepressants (CANMAT [Yatham 2018]; WFSBP [Grunze 2018]). Patients presenting with depressive symptoms should be screened for bipolar disorder. <b>Selegiline is not FDA approved for the treatment of bipolar depression. </b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use oral products with caution in patients with renal impairment; orally disintegrating tablets are not recommended in patients with severe renal impairment (CrCl &lt;30 mL/minute) and end-stage renal disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: According to many of MAOI manufacturers, use within 10 days prior to elective surgery is contraindicated. The decision to continue or withhold MAOIs must be done in collaboration with the patient's psychiatrist. Currently, an MAO-safe anesthetic technique that excludes the use of meperidine and indirect-acting adrenergic agonists is recommended for patients requiring continued MAOI therapy (Huyse 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Orally disintegrating tablet: May cause irritation of buccal mucosa including swallowing pain, mouth pain, discrete areas of focal reddening, multiple foci of reddening, edema, and/or ulceration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Phenylalanine: Orally disintegrating tablet: May contain phenylalanine; use caution in patients with phenylketonuria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transdermal patch: Avoid exposure of application site and surrounding area to direct external heat sources (eg, heating pads, electric blankets, heat lamps, saunas, hot tubs, heated water beds, and prolonged direct sunlight); may increase drug absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antidepressant discontinuation syndrome: Abrupt discontinuation or interruption of antidepressant therapy has been associated with a discontinuation syndrome. Symptoms arising may vary with antidepressant however commonly include nausea, vomiting, diarrhea, headaches, lightheadedness, dizziness, diminished appetite, sweating, chills, tremors, paresthesias, fatigue, somnolence, and sleep disturbances (eg, vivid dreams, insomnia). Less common symptoms include electric shock-like sensations, cardiac arrhythmias (more common with tricyclic antidepressants), myalgias, parkinsonism, arthralgias, and balance difficulties. Psychological symptoms may also emerge such as agitation, anxiety, akathisia, panic attacks, irritability, aggressiveness, worsening of mood, dysphoria, mood lability, hyperactivity, mania/hypomania, depersonalization, decreased concentration, slowed thinking, confusion, and memory or concentration difficulties. Greater risks for developing a discontinuation syndrome have been associated with antidepressants with shorter half-lives, longer durations of treatment, and abrupt discontinuation. More severe symptoms have also been associated with MAOIs. For antidepressants of short or intermediate half-lives, symptoms may emerge within 2 to 5 days after treatment discontinuation and last 7 to 14 days (APA 2010; Fava 2006; Haddad 2001; Shelton 2001; Warner 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">• Antiparkinsonian discontinuation syndrome: Abrupt discontinuation or interruption of antiparkinsonian therapy has been associated with a discontinuation syndrome, which may resemble neuroleptic malignant syndrome; symptoms may include elevated temperature, muscular rigidity, altered consciousness, and autonomic instability.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tyramine-containing products: Nonselective MAO inhibition may occur with transdermal delivery and is necessary for antidepressant efficacy. Hypertensive crisis as a result of ingesting tyramine-rich foods is always a concern with nonselective MAO inhibition. Although transdermal delivery minimizes inhibition of MAO-A in the gut, there are limited data with higher transdermal doses; dietary modifications are recommended with doses ≥9 mg/24 hours. Discontinue therapy immediately if hypertensive crisis occurs. With the oral product, MAO-B selective inhibition should not pose a problem with tyramine-containing products as long as the typical oral doses are employed, however, rare hypertensive reactions have been reported. Increased risk of nonselective MAO inhibition occurs with oral capsule/tablet doses &gt;10 mg/day or orally disintegrating tablet doses &gt;2.5 mg/day.</p></div>
<div class="block foc drugH1Div" id="F220292"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch 24 Hour, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Emsam: 6 mg/24 hr (1 ea, 30 ea); 9 mg/24 hr (1 ea, 30 ea); 12 mg/24 hr (1 ea, 30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Disintegrating, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zelapar: 1.25 mg [contains aspartame; grapefruit flavor]</p></div>
<div class="block geq drugH1Div" id="F220278"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F220301"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Selegiline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1.42 - $2.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, 24-hour</b> (Emsam Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/24 hrs (per each): $81.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">9 mg/24 hrs (per each): $81.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12 mg/24 hrs (per each): $81.71</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, orally-disintegrating</b> (Zelapar Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1.25 mg (per each): $114.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Selegiline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2.10</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868215"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg</p></div>
<div class="block adm drugH1Div" id="F2730983"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Orally disintegrating tablet: Remove blister from sachet immediately before administering. Do not attempt to push tablet through blister's foil backing; peel backing off and gently remove tablet with dry hands. Administer in morning before breakfast; do not swallow; place on top of tongue and allow to dissolve. Avoid food or liquid 5 minutes before and after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b> Transdermal: Apply to clean, dry, intact skin to the upper torso (below the neck and above the waist), upper thigh, or outer surface of the upper arm. Do not apply to skin that is hairy, oily, irritated, broken, scarred, or calloused. Do not place under tight clothing. Apply at the same time each day and rotate application sites. Wash hands with soap and water after handling. Avoid touching the sticky side of the patch. Discard any used or unused patches by folding adhesive ends together and discard properly in trash.</p></div>
<div class="block admp drugH1Div" id="F52613843"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Topical: Transdermal: Apply to clean, dry, intact skin to the upper torso (below the neck and above the waist), upper thigh, or outer surface of the upper arm. Do not apply to skin that is hairy, oily, irritated, broken, scarred, or calloused. Do not place under tight clothing. Apply at the same time each day and rotate application sites. Wash hands with soap and water after handling. Avoid touching the sticky side of the patch. Discard any used or unused patches by folding adhesive ends together and discard properly in trash.</p></div>
<div class="block meg drugH1Div" id="F7874988"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Emsam: <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2Fucm088589.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9%2Bevs591MjKrfB30zg8bRlD8TyV8fRCkunZB5e1nM5aQ%3D%3D&amp;TOPIC_ID=9883" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088589.pdf</a></p></div>
<div class="block use drugH1Div" id="F220295"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar) (transdermal patch):</b> Treatment of unipolar major depressive disorder in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease, adjunctive therapy (oral products):</b> Adjunct in the management of patients with Parkinson disease exhibiting decreased response to carbidopa/levodopa therapy.</p></div>
<div class="block off-label drugH1Div" id="F25744903"><span class="drugH1">Use: Off-Label: Adult</span><p>Parkinson disease, monotherapy</p></div>
<div class="block mst drugH1Div" id="F220361"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Selegiline may be confused with Salagen, sertraline, Serzone, Stelazine </p>
<p style="text-indent:-2em;margin-left:4em;">Eldepryl may be confused with Elavil, enalapril</p>
<p style="text-indent:-2em;margin-left:4em;">Zelapar may be confused with zaleplon, Zemplar, zolpidem, ZyPREXA Zydis</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F220347"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> Monoamine Oxidase</p></div>
<div class="block dri drugH1Div" id="F220287"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Monoamine Oxidase Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-/Beta-Agonists (Indirect-Acting): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Agonists: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Amisulpride (Oral). Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Amphetamines. While linezolid and tedizolid may interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apraclonidine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Apraclonidine. Monoamine Oxidase Inhibitors may increase the serum concentration of Apraclonidine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ARIPiprazole Lauroxil. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asenapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Asenapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: Monoamine Oxidase Inhibitors may enhance the neurotoxic (central) effect of Atomoxetine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atropine (Ophthalmic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Atropine (Ophthalmic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Benperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: The use of benzhydrocodone is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation. If coadministration is required, use test doses and frequent titration of small benzhydrocodone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Monoamine Oxidase Inhibitors may increase the serum concentration of Betahistine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bezafibrate: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Bezafibrate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Blonanserin. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: Selegiline may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Brexpiprazole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Ophthalmic): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Ophthalmic). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Topical). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of BuPROPion. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Butorphanol: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Do not use carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbinoxamine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Carbinoxamine. Specifically, the anticholinergic effects of carbinoxamine may be enhanced and prolonged. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Cariprazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cerebrolysin: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of ChlorproMAZINE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: Selegiline may enhance the serotonergic effect of ClomiPRAMINE. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clothiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Clothiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Codeine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproheptadine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Cyproheptadine. Cyproheptadine may diminish the serotonergic effect of Monoamine Oxidase Inhibitors. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Deutetrabenazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Dexmethylphenidate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This may cause serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diamorphine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Diamorphine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diethylpropion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Diethylpropion. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dihydrocodeine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Consider avoiding use of dihydrocodeine while the patient is taking monoamine oxidase inhibitors (MAOIs) and for 2 weeks after MAOI discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diphenoxylate: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Domperidone. Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of Monoamine Oxidase Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOPamine: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of DOPamine.  Management: Initiate dopamine at no greater than one-tenth (1/10) of the usual dose in patients who are taking (or have taken within the last 2 to 3 weeks) monoamine oxidase inhibitors. Monitor for an exaggerated hypertensive response to dopamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxapram: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Doxapram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of DroPERidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethinyl Estradiol-Containing Products: May increase the serum concentration of Selegiline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flupentixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Flupentixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of FluPHENAZine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Haloperidol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROcodone. HYDROcodone may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.  Management: Consider alternatives to this combination when possible. If coadministration is required, use test doses, titrate small doses frequently, and monitor patients closely for evidence of serotonergic and opioid toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROmorphone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.  Management: Coadministration of hydromorphone and monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) is not recommended. If required, use test doses, titrate small doses frequently, and monitor for CNS and respitatory depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iloperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: Selegiline may enhance the serotonergic effect of Imipramine. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Indoramin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Selegiline may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic antiseizure drugs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isometheptene: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Isometheptene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Monoamine Oxidase Inhibitors may enhance the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: May enhance the orthostatic hypotensive effect of Monoamine Oxidase Inhibitors (Type B).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonordefrin: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Levonordefrin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Loxapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lumateperone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Lurasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maprotiline: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meptazinol: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Meptazinol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaraminol: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Metaraminol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, monoamine oxidase inhibitors may enhance dopamine blockade, possible increasing the risk for neuroleptic malignant syndrome. Methotrimeprazine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methyldopa: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Methyldopa. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Monoamine Oxidase Inhibitors (Type B) may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Methylphenidate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Monoamine Oxidase Inhibitors may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molindone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Molindone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): May enhance the hypertensive effect of Monoamine Oxidase Inhibitors (Type B). Monoamine Oxidase Inhibitors (Antidepressant) may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Type B): May enhance the serotonergic effect of other Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Morphine (Systemic): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Morphine (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalbuphine: Monoamine Oxidase Inhibitors may enhance the CNS depressant effect of Nalbuphine. Nalbuphine may enhance the hypertensive effect of Monoamine Oxidase Inhibitors. Nalbuphine may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.  Management: Use of nalbuphine is not recommended in patients taking MAOIs, or within 14 days of stopping MAOI therapy. If urgent nalbuphine use is needed, use test doses and frequent titration while monitoring blood pressure, CNS depression, and serotonergic toxicity<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: Selegiline may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefopam: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Nefopam. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Norepinephrine: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Norepinephrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Normethadone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Normethadone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of OLANZapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opium: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Opium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: Use of oxycodone is not recommended for patients taking MAOIs or within 14 days of MAOI discontinuation. If combined, use test doses and frequent titration of small doses while monitoring blood pressure, CNS depression, and signs of serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyMORphone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paliperidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Paliperidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Periciazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Periciazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Perphenazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pheniramine: May enhance the anticholinergic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pimozide. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Anti-Parkinson Agents (Monoamine Oxidase Inhibitor) may diminish the therapeutic effect of Pipamperone [INT]. Pipamperone [INT] may diminish the therapeutic effect of Anti-Parkinson Agents (Monoamine Oxidase Inhibitor). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pipamperone [INT]: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Pipamperone [INT]. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pizotifen: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Pizotifen. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Polyethylene Glycol-Electrolyte Solution. Specifically, the risk of seizure may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prochlorperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Prochlorperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Promazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of QUEtiapine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reboxetine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reboxetine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Remifentanil: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Remifentanil. Specifically, the risk for opioid toxicity (eg, respiratory depression) may be increased. Remifentanil may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.  Management: The use of remifentanil is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation. If coadministration is required, use test doses and titrate small doses of remifentanil frequently.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine. Monitor closely for paradoxical effects of reserpine (eg, excitation, hypertension).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of RisperiDONE. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Selegiline. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): Monoamine Oxidase Inhibitors (Type B) may enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (Moderate Risk, Miscellaneous): Monoamine Oxidase Inhibitors (Type B) may enhance the serotonergic effect of Serotonergic Agents (Moderate Risk, Miscellaneous). This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: Selegiline may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): May enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Type B). This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: Selegiline may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sertindole. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sevoflurane: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Sevoflurane. Specifically, the risk of hemodynamic instability may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure or loss of consciousness may be increased in patients with significant sodium phosphate-induced fluid or electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Solriamfetol. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: Monoamine Oxidase Inhibitors (Type B) may enhance the serotonergic effect of St John's Wort. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the risk for serotonin syndrome or opioid toxicities (eg, respiratory depression, coma) may be increased. Management: Sufentanil should not be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for serotonin syndrome and/or excessive CNS depression.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulpiride: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Sulpiride. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tapentadol: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the additive effects of norepinephrine may lead to adverse cardiovascular effects. Tapentadol may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrozoline (Nasal): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thioridazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiothixene: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Thiothixene. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Selegiline may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trifluoperazine: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Trifluoperazine. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tyrosine: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Viloxazine: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ziprasidone: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Ziprasidone. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Zuclopenthixol. Specifically, the risk of seizures may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F220308"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Concurrent ingestion of foods rich in tyramine, dopamine, tyrosine, phenylalanine, tryptophan, or caffeine may cause sudden and severe high blood pressure (hypertensive crisis or serotonin syndrome). Beverages containing tyramine (eg, hearty red wine and beer) may increase toxic effects. Management: Avoid tyramine-containing foods (aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). Food’s freshness is also an important concern; improperly stored or spoiled food can create an environment in which tyramine concentrations may increase. Avoid foods containing dopamine, tyrosine, phenylalanine, tryptophan, or caffeine. Avoid beverages containing tyramine (Walker 1996).</p></div>
<div class="block pri drugH1Div" id="F2730972"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to the use of selegiline in pregnant patients for the treatment of depression (Bauer 2017) or Parkinson disease (Olivola 2020; Seier 2017) is limited. Agents other than selegiline may be preferred for the treatment of major depressive disorder or Parkinson disease in pregnant patients (Olivola 2020; WFSBP [Bauer 2013]).</p></div>
<div class="block brc drugH1Div" id="F16571117"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if selegiline is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to the use of selegiline in breastfeeding patients is limited (Bauer 2017). Due to the potential for serious adverse reactions in the breastfeeding infant, breastfeeding is not recommended by the manufacturer. If selegiline is discontinued, wait 5 days after the final selegiline patch is removed, or 7 days after the last oral disintegrating tablet is taken before breastfeeding.</p></div>
<div class="block dic drugH1Div" id="F2730982"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid or limit tyramine-containing foods/beverages (product and/or dose-dependent). Some examples include aged or matured cheese, air-dried or cured meats (including sausages and salamis), fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce and other soybean condiments. Food’s freshness is also an important concern; improperly stored or spoiled food can create an environment where tyramine concentrations may increase (Walker 1996).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Transdermal: 9 mg/24 hours or 12 mg/24 hours: Avoid tyramine-rich foods or beverages beginning the first day of treatment and for 2 weeks after discontinuation or dose reduction to 6 mg/24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Orally disintegrating tablet: Do not administer with food or liquid; avoid food or liquid 5 minutes before and after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Some products may contain phenylalanine.</p></div>
<div class="block mop drugH1Div" id="F220290"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP; mood and behavior (increased anxiety, presence of mania or agitation); suicidal ideation (especially during the initial 1 to 2 months of therapy or when doses are increased or decreased).</p></div>
<div class="block pha drugH1Div" id="F220281"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Potent, irreversible inhibitor of monoamine oxidase (MAO). Selegiline has a greater affinity for MAO-B compared to MAO-A (intestinal MAO is predominantly type A; in the brain, both isoenzymes exist). In the CNS, MAO plays a major role in the catabolism of dopamine, serotonin, norepinephrine, and epinephrine. At lower doses, selegiline can serve as a selective inhibitor of MAO-B; however, as selegiline concentrations increase, MAO-B selectivity is lost. Selegiline may increase dopaminergic activity by interfering with dopamine reuptake at the synapse. Effects may also be mediated through its metabolites, including amphetamine and methamphetamine, which interfere with neuronal uptake and enhance release of several neurotransmitters (eg, norepinephrine, dopamine, serotonin). The extent to which these metabolites contribute to the effects of selegiline are unknown. Plasma concentrations achieved via administration of oral dosage forms in recommended doses confer selective inhibition of MAO type B. When administered transdermally, selegiline achieves higher blood levels with significantly lower exposure for all metabolites when compared with oral dosing. Attention to the dose-dependent nature of selegiline’s selectivity is necessary if it is to be used without diet and concomitant drug restrictions.</p></div>
<div class="block phk drugH1Div" id="F220297"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule/tablet: Bioavailability increases 3- to 4-fold when taken with food.</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: Rapid. Food decreases C<sub>max</sub> and AUC to ~60% of fasting state.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 85% to 90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, primarily via CYP2B6, CYP2C9, CYP3A4, and CYP2A6 (minor) to active (N-desmethylselegiline, amphetamine, methamphetamine) and inactive metabolites. Capsules/tablets undergo extensive first-pass metabolism, resulting in higher exposure to metabolites compared with other dosage forms (Azzaro 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: 4% (Azzaro 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet (ODT): Sublingual administration of ODT has greater bioavailability than capsule dependent upon time in buccal cavity. Up to 30% absorption if held for 1 minute without swallowing (Tábi 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: 73% (Azzaro 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 10 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: 20 hours (Azzaro 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: 0.86 hours (Azzaro 2007).</p>
<p style="text-indent:-2em;margin-left:4em;">Orally disintegrating tablet: 10 to 15 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Transdermal: 20 hours (Azzaro 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily metabolites); feces.</p></div>
<div class="block phksp drugH1Div" id="F51159876"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Orally disintegrating tablets: Patients with moderate renal impairment (CrCl 31 to 50 mL/minute) had a 34% to 67% increase in exposure to the active metabolites methamphetamine and amphetamine. Patients with end-stage renal disease off dialysis had a 4-fold increase in exposure to the active metabolites methamphetamine and amphetamine.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Orally disintegrating tablets: Patients with mild hepatic impairment (Child-Pugh score 5 to 6) had a 1.5-fold higher AUC and C<sub>max</sub> of selegiline and a 1.4-fold and 1.2-fold higher, respectively, AUC and C<sub>max</sub> of the metabolite desmethylselegiline. In patients with moderate hepatic impairment (Child-Pugh score 7 to 9), AUC of selegiline and desmethylselegiline increased 1.5-fold and 1.8-fold, respectively. Patients with severe hepatic impairment (Child-Pugh score &gt;9) had a 4-fold increased AUC of selegiline, 3-fold increased C<sub>max</sub> of selegiline, 1.25-fold increased AUC of desmethylselegiline and 50% reduced C<sub>max</sub> of desmethylselegiline.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Systemic exposure is about twice as high in elderly patients when given a single 10 mg oral dose.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F220302"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo-selegiline</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Brintenal | Jumex | Kinabide</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Amboneural | Cognitiv | Jumex | Selegilin | Xilopar</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Selgene</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Jumex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Jamax | Jumex | Niar | Selegos</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de selegilina | Deprilan | Elepril | Jumexil | Niar | Parkexin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Jumexal | Selecim | Selegilin helvepharm</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Comenter | Selgina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Fu an | Jin si ping | Selegilin-ratiopharm | Si ji ning</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cebrocal | Jumexal | Sedicel | Selegil</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo seleg | Cognitiv | Jumex | Niar | Selegilin-ratiopharm | Selegos | Sepatrem</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Jutagilin | Maotil | Movergan | Selegam | Selegilin | Selegilin al | Selegilin CT | Selegilin hexal | Selegilin Sandoz | Selegilin stada | Selemerck | Selepark | Selgimed | Silin | Xilopar</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Jumex</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Comenter | Selegil | Selexss</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Jumex | Selegilin hexal</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Jumex | Parkineast | Tonus</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Selegilina davur | Selegilina profas</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Selegilin alpharma | Selegilin generics</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Deprenyl | Otrasel | Selegiline Biogaran | Selegiline g gam | Selegiline merck | Selegiline Ratiopharm | Selegiline Teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Centrapryl | Eldepryl | Selegiline | Selegiline cox | Selegiline kent | Selegiline sandoz | Stillime | Stilline | Vivapryl | Zelapar</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cosmopril | Legil | Procythol | Resostyl</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-selegiline | Jumex | Sefmex | Selgin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Jumex</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cognitiv | Jumex | Primulex | Selegilin al | Selegilin hexal | Selegilin neuraxpharm | Selegiline merck</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Jumex</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Clondepryl | Eldepryl</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Jumex | Selegiline | Selegiline Teva</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Elegelin | Jumex | Selerin | Selgin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Egibren | Jumex | Selecom | Seledat | Selegilina | Selegilina eg | Xilopar</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Selecim</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fp | FP OD | Selegiline HCL | Selegiline hydrochloride Mylan</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Selerin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Jumex | Mao-b</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Jumex | Segan | Selegiline</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Jumex | Segan | Selegiline</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Niar</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Julegil | Jumalline | Jumex | Sefmex | Selegos</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Selegiline | Selegiline HCL</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Jumex | Selegilin | Selegilin al | Selegilin mylan | Selegilin stada | Selegilin-neuraxpharm</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo-selegiline | Eldepryl | Selgene</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Kinabide | Selegil | Selegilina | Selegilina clorhidrato</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Jumex | Selegiline | Selegos | Zelapar</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Jumalline | Jumex | Selgin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo-selin | Jumex | Movergan | Niar | Segan | Selenor | Selerin | Selgin | Selgres</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Carbex | Eldepryl | Selegiline HCL | Zelapar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Jumex | Selegilina | Xilopar</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Jumex | Niar | Ultravital</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Als selegilina | Cognitiv | Jumex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Jumex | Stillin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-selegiline</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Selegilin alpharma | Selegilin hydroklorid norton healthcare | Selegilin Merck NM | Selegilin mylan | Xilopar</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Jumex | Selegos</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Jumex</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Cognitiv | Jumex | Selegil</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Elegelin | Julab | Jumex | Kinline | Sefmex | Selgene | Seline</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Deprenyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Moverdin | Seldepar</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Jumexal | Parkryl | Seginine | Selegos | Selegyl | Selezin | Seline | Siltin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Jumex | Segan | Selegiline</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dep | Gilenpar | Jumex | Kinabide | Neurogiline | Selegit | Sygylium</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Jumex</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Eldepryl | Parkilyne</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychiatric Association (APA). Treatment recommendations for patients with major depressive disorder. 3rd ed. May 2010. Available at http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apotex.1">
<a name="Apotex.1"></a>Apo-Selegiline [product monograph]. Weston, Ontario, Canada: Apotex Inc; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17715422">
<a name="17715422"></a>Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. <i>J Clin Pharmacol.</i> 2007;47(10):1256-1267. doi:10.1177/0091270007304779<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/17715422/pubmed" id="17715422" target="_blank">17715422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry</i>. 2015;16(2):76-95. doi: 10.3109/15622975.2014.1001786.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28501290">
<a name="28501290"></a>Bauer RL, Orfei J, Wichman CL. Use of transdermal selegiline in pregnancy and lactation: a case report. <i>Psychosomatics</i>. 2017;58(4):450-452. doi: 10.1016/j.psym.2017.03.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/28501290/pubmed" id="28501290" target="_blank">28501290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23897874">
<a name="23897874"></a>Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2013;81(5):463-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/23897874/pubmed" id="23897874" target="_blank">23897874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Emsam (selegiline transdermal system) [prescribing information]. Morgantown, WV: Mylan Specialty LP; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683858">
<a name="16683858"></a>Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):14-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/16683858/pubmed" id="16683858" target="_blank">16683858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23279439">
<a name="23279439"></a>Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. <i>Eur J Neurol.</i> 2013;20(1):5-15. doi:10.1111/j.1468-1331.2012.03866.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/23279439/pubmed" id="23279439" target="_blank">23279439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29570866">
<a name="29570866"></a>Fox SH, Katzenschlager R, Lim SY, et al; Movement Disorder Society Evidence-Based Medicine Committee. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. <i>Mov Disord.</i> 2018;33(8):1248-1266. doi:10.1002/mds.27372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/29570866/pubmed" id="29570866" target="_blank">29570866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8102552">
<a name="8102552"></a>Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. <i>Biol Psychiatry</i>. 1993;33(10):700-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/8102552/pubmed" id="8102552" target="_blank">8102552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29098925">
<a name="29098925"></a>Grunze H, Vieta E, Goodwin GM, et al; Members of the WFSBP Task Force on Bipolar Affective Disorders working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World J Biol Psychiatry</i>. 2018;19(1):2-58. doi: 10.1080/15622975.2017.1384850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/29098925/pubmed" id="29098925" target="_blank">29098925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.1">
<a name="Hirsch.1"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 1, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16384803">
<a name="16384803"></a>Huyse FJ, Touw DJ, van Schijndel RS, et al, “Psychotropic Drugs and the Perioperative Period: A Proposal for a Guideline in Elective Surgery,” <i>Psychosomatics</i>, 2006, 47(1):8-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/16384803/pubmed" id="16384803" target="_blank">16384803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11499649">
<a name="11499649"></a>Ito D, Amano T, Sato H, Fukuuchi Y. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease. <i>J Neurol</i>. 2001;248(6):533-534. doi:10.1007/s004150170168<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/11499649/pubmed" id="11499649" target="_blank">11499649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15310558">
<a name="15310558"></a>Ives NJ, Stowe RL, Marro J, et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. <i>BMJ</i>. 2004;329(7466):593. doi:10.1136/bmj.38184.606169.AE<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/15310558/pubmed" id="15310558" target="_blank">15310558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28857772">
<a name="28857772"></a>Mizuno Y, Hattori N, Kondo T, et al. A randomized double-blind placebo-controlled phase III trial of selegiline monotherapy for early Parkinson disease. <i>Clin Neuropharmacol.</i> 2017;40(5):201-207. doi:10.1097/WNF.0000000000000239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/28857772/pubmed" id="28857772" target="_blank">28857772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31045589">
<a name="31045589"></a>Mizuno Y, Hattori N, Kondo T, et al. Long-term selegiline monotherapy for the treatment of early Parkinson disease. <i>Clin Neuropharmacol</i>. 2019;42(4):123-130. doi:10.1097/WNF.0000000000000343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/31045589/pubmed" id="31045589" target="_blank">31045589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15650498">
<a name="15650498"></a>Mohammadi MR, Ghanizadeh A, Alaghband-Rad J, et al, "Selegiline in Comparison With Methylphenidate in Attention Deficit Hyperactivity Disorder Children and Adolescents in a Double-Blind, Randomized Clinical Trial," <i>J Child Adolesc Psychopharmacol</i>, 2004, 14(3):418-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/15650498/pubmed" id="15650498" target="_blank">15650498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11154095">
<a name="11154095"></a>Montastruc JL, Chaumerliac C, Desboeuf K, et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. <i>Clin Neuropharmacol</i>. 2000;23(5):271-275. doi:10.1097/00002826-200009000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/11154095/pubmed" id="11154095" target="_blank">11154095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11402154">
<a name="11402154"></a>Olanow CW, Watts RL, and Koller WC, "An Algorithm (Decision Tree) for the Management of Parkinson's Disease (2001): Treatment Guidelines," <i>Neurology</i>, 2001, 56(11 Suppl 5):1-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/11402154/pubmed" id="11402154" target="_blank">11402154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32140133">
<a name="32140133"></a>Olivola S, Xodo S, Olivola E, Cecchini F, Londero AP, Driul L. Parkinson's disease in pregnancy: a case report and review of the literature. <i>Front Neurol</i>. 2020;10:1349. doi:10.3389/fneur.2019.01349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/32140133/pubmed" id="32140133" target="_blank">32140133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9710028">
<a name="9710028"></a>Pålhagen S, Heinonen EH, Hägglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. <i>Neurology</i>. 1998;51(2):520-525. doi:10.1212/wnl.51.2.520<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/9710028/pubmed" id="9710028" target="_blank">9710028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8417384">
<a name="8417384"></a>Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.<i> N Engl J Med.</i> 1993;328(3):176-183. doi:10.1056/NEJM199301213280305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/8417384/pubmed" id="8417384" target="_blank">8417384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30791698">
<a name="30791698"></a>Ricciardi L, Pringsheim T, Barnes TRE, et al. Treatment recommendations for tardive dyskinesia. <i>Can J Psychiatry</i>. 2019;64(6):388-399. doi:10.1177/0706743719828968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/30791698/pubmed" id="30791698" target="_blank">30791698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9330778">
<a name="9330778"></a>Rohatagi S, Barrett JS, DeWitt KE, Morales RJ. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. <i>Biopharm Drug Dispos.</i> 1997;18(7):567-584. doi:10.1002/(sici)1099-081x(199710)18:7&lt;567::aid-bdd49&gt;3.0.co;2-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/9330778/pubmed" id="9330778" target="_blank">9330778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28506531">
<a name="28506531"></a>Seier M, Hiller A. Parkinson's disease and pregnancy: An updated review. <i>Parkinsonism Relat Disord</i>. 2017;40:11-17. doi:10.1016/j.parkreldis.2017.05.007.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/28506531/pubmed" id="28506531" target="_blank">28506531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAPharma.1">
<a name="AAPharma.1"></a>Selegiline [product monograph] tablets. Vaughan, Ontario, Canada: AA Pharma Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novitium.1">
<a name="Novitium.1"></a>Selegiline Hydrochloride Capsules [prescribing information]. East Windsor, NJ: Novitium Pharma LLC; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-i3Pharma.1">
<a name="i3Pharma.1"></a>Selegiline Hydrochloride Tablets [prescribing information]. Warminster, PA: i3 Pharmaceuticals LLC; December 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16730214">
<a name="16730214"></a>Shapiro MA, Chang YL, Munson SK, Okun MS, Fernandez HH. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. <i>Parkinsonism Relat Disord</i>. 2006;12(6):392-395. doi:10.1016/j.parkreldis.2006.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/16730214/pubmed" id="16730214" target="_blank">16730214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton, RC. Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23506388">
<a name="23506388"></a>Tábi T, Szökő E, Vécsei L, Magyar K. The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.<i> Expert Opin Drug Metab Toxicol.</i> 2013;9(5):629-636. doi:10.1517/17425255.2013.781152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/23506388/pubmed" id="23506388" target="_blank">23506388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8889911">
<a name="8889911"></a>Walker SE, Shulman KI, Tailor S, Gardner D. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. <i>J Clin Psychopharmacol .</i>1996;16(5):383-388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/8889911/pubmed" id="8889911" target="_blank">8889911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi: 10.1111/bdi.12609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/selegiline-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bausch.1">
<a name="Bausch.1"></a>Zelapar (selegiline) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; June 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9883 Version 410.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
